The Cognitive Impact of Gabapentinoids in Patients with Fibromyalgia
Research type
Research Study
Full title
The Cognitive Impact of Gabapentinoids in Patients with Fibromyalgia
IRAS ID
181265
Contact name
Bernhard Frank
Contact email
Sponsor organisation
The Walton Centre NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 17 days
Research summary
In clinical practice, patients with fibromyalgia are often prescribed gabapentinoids (pregabalin or gabapentin) and present with problems related to memory and concentration. These symptoms may be related to fibromyalgia or drug induced. Patients affected by these symptoms may not gain optimal benefit from the psychological and physical treatment provided by a pain management programme. Limited research evidence exists to suggest that gabapentinoids improve pain and function.
The aim of this study is to investigate the impact of Gabapentinoids on cognitive function in patients with fibromyalgia. We will use a naturally occurring population of patients currently taking gabapentinoids but not experiencing significant pain relief or experiencing considerable side effects who wish to be weaned off them as part of routine care. We will assess patients cognitive function before and after the weaning process and compare this to a control group of healthy volunteers. Our primary outcome will be the extent and quality of the impact gabapentinoids have on cognitive function in patients with fibromyalgia. Results will inform the development of a future study.REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
15/NE/0195
Date of REC Opinion
29 May 2015
REC opinion
Favourable Opinion